Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study

E. Llurba, F. Crispi, F. Crovetto, L. Youssef, JL. Delgado, I. Puig, J. Mora, L. Krofta, K. Mackova, A. Martinez-Varea, A. Tubau, A. Ruiz, A. Paya, M. Prat, F. Chantraine, C. Comas, A. Kajdy, MF. Lopez-Tinajero, F. Figueras, E. Gratacos, PE37 study group

. 2024 ; 14 (3) : e076201. [pub] 20240308

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu protokol klinické studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006762

INTRODUCTION: Pre-eclampsia affects ~5%-7% of pregnancies. Although improved obstetric care has significantly diminished its associated maternal mortality, it remains a leading cause of maternal morbidity and mortality in the world. Term pre-eclampsia accounts for 70% of all cases and a large proportion of maternal-fetal morbidity related to this condition. Unlike in preterm pre-eclampsia, the prediction and prevention of term pre-eclampsia remain unsolved. Previously proposed approaches are based on combined third-trimester screening and/or prophylactic drugs, but these policies are unlikely to be widely implementable in many world settings. Recent evidence shows that the soluble fms-like tyrosine kinase-1 (s-Flt-1) to placental growth factor (PlGF) ratio measured at 35-37 weeks' gestation predicts term pre-eclampsia with an 80% detection rate. Likewise, recent studies demonstrate that induction of labour beyond 37 weeks is safe and well accepted by women. We hypothesise that a single-step universal screening for term pre-eclampsia based on sFlt1/PlGF ratio at 35-37 weeks followed by planned delivery beyond 37 weeks reduces the prevalence of term pre-eclampsia without increasing the caesarean section rates or worsening the neonatal outcomes. METHODS AND ANALYSIS: We propose an open-label randomised clinical trial to evaluate the impact of a screening of term pre-eclampsia with the sFlt-1/PlGF ratio followed by planned delivery in asymptomatic nulliparous women at 35-37 weeks. Women will be assigned 1:1 to revealed (sFlt-1/PlGF known to clinicians) versus concealed (unknown) arms. A cut-off of >90th centile is used to define the high risk of subsequent pre-eclampsia and offer planned delivery from 37 weeks. The efficacy variables will be analysed and compared between groups primarily following an intention-to-treat approach, by ORs and their 95% CI. This value will be computed using a Generalised Linear Mixed Model for binary response (study group as fixed effect and the centre as intercept random effect). ETHICS AND DISSEMINATION: The study is conducted under the principles of Good Clinical Practice. This study was accepted by the Clinical Research Ethics Committee of Hospital Clinic Barcelona on 20 November 2020. Subsequent approval by individual ethical committees and competent authorities was granted. The study results will be published in peer-reviewed journals and disseminated at international conferences. TRIAL REGISTRATION NUMBER: NCT04766866.

000      
00000naa a2200000 a 4500
001      
bmc24006762
003      
CZ-PrNML
005      
20240423155502.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmjopen-2023-076201 $2 doi
035    __
$a (PubMed)38458783
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Llurba, Elisa $u Obstetrics and Gynecology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
245    10
$a Multicentre randomised trial of screening with sFlt1/PlGF and planned delivery to prevent pre-eclampsia at term: protocol of the PE37 study / $c E. Llurba, F. Crispi, F. Crovetto, L. Youssef, JL. Delgado, I. Puig, J. Mora, L. Krofta, K. Mackova, A. Martinez-Varea, A. Tubau, A. Ruiz, A. Paya, M. Prat, F. Chantraine, C. Comas, A. Kajdy, MF. Lopez-Tinajero, F. Figueras, E. Gratacos, PE37 study group
520    9_
$a INTRODUCTION: Pre-eclampsia affects ~5%-7% of pregnancies. Although improved obstetric care has significantly diminished its associated maternal mortality, it remains a leading cause of maternal morbidity and mortality in the world. Term pre-eclampsia accounts for 70% of all cases and a large proportion of maternal-fetal morbidity related to this condition. Unlike in preterm pre-eclampsia, the prediction and prevention of term pre-eclampsia remain unsolved. Previously proposed approaches are based on combined third-trimester screening and/or prophylactic drugs, but these policies are unlikely to be widely implementable in many world settings. Recent evidence shows that the soluble fms-like tyrosine kinase-1 (s-Flt-1) to placental growth factor (PlGF) ratio measured at 35-37 weeks' gestation predicts term pre-eclampsia with an 80% detection rate. Likewise, recent studies demonstrate that induction of labour beyond 37 weeks is safe and well accepted by women. We hypothesise that a single-step universal screening for term pre-eclampsia based on sFlt1/PlGF ratio at 35-37 weeks followed by planned delivery beyond 37 weeks reduces the prevalence of term pre-eclampsia without increasing the caesarean section rates or worsening the neonatal outcomes. METHODS AND ANALYSIS: We propose an open-label randomised clinical trial to evaluate the impact of a screening of term pre-eclampsia with the sFlt-1/PlGF ratio followed by planned delivery in asymptomatic nulliparous women at 35-37 weeks. Women will be assigned 1:1 to revealed (sFlt-1/PlGF known to clinicians) versus concealed (unknown) arms. A cut-off of >90th centile is used to define the high risk of subsequent pre-eclampsia and offer planned delivery from 37 weeks. The efficacy variables will be analysed and compared between groups primarily following an intention-to-treat approach, by ORs and their 95% CI. This value will be computed using a Generalised Linear Mixed Model for binary response (study group as fixed effect and the centre as intercept random effect). ETHICS AND DISSEMINATION: The study is conducted under the principles of Good Clinical Practice. This study was accepted by the Clinical Research Ethics Committee of Hospital Clinic Barcelona on 20 November 2020. Subsequent approval by individual ethical committees and competent authorities was granted. The study results will be published in peer-reviewed journals and disseminated at international conferences. TRIAL REGISTRATION NUMBER: NCT04766866.
650    _2
$a novorozenec $7 D007231
650    _2
$a těhotenství $7 D011247
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a preeklampsie $x diagnóza $x prevence a kontrola $x epidemiologie $7 D011225
650    _2
$a receptor 1 pro vaskulární endoteliální růstový faktor $7 D040281
650    _2
$a placentární růstový faktor $7 D000072483
650    _2
$a císařský řez $7 D002585
650    _2
$a biologické markery $7 D015415
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a multicentrické studie jako téma $7 D015337
655    _2
$a protokol klinické studie $7 D000078325
655    _2
$a časopisecké články $7 D016428
700    1_
$a Crispi, Fatima $u BCNatal, Fetal Medicine Research Center, Hospital Clínic and Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain
700    1_
$a Crovetto, Francesca $u Hospital Clinic de Barcelona, Barcelona, Spain $1 https://orcid.org/0000000301407411
700    1_
$a Youssef, Lina $u IDIBAPS, Barcelona, Spain
700    1_
$a Delgado, Juan Luis $u Unidad Medicina Fetal Murcia, IMIB Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
700    1_
$a Puig, Isabel $u Unidad Medicina Fetal Murcia, IMIB Arrixaca, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
700    1_
$a Mora, Josefina $u Biochemistry, Hospital Sant Pau, Barcelona, Spain
700    1_
$a Krofta, Ladislav $u Institute for the Care of Mother and Child, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Mackova, Katerina $u Institute for the Care of Mother and Child, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Martinez-Varea, Alicia $u Hospital Politécnico y Universitario La Fe, Valencia, Spain
700    1_
$a Tubau, Albert $u Obstetrician, Son Llàtzer Hospital, Palma de Mallorca, Illes Balears, Spain $1 https://orcid.org/0000000154600763
700    1_
$a Ruiz, Aina $u Obstetrician, Son Llàtzer Hospital, Palma de Mallorca, Illes Balears, Spain
700    1_
$a Paya, Antoni $u Hospital del Mar, Barcelona, Spain
700    1_
$a Prat, Maria $u Hospital del Mar, Barcelona, Spain
700    1_
$a Chantraine, Frederic $u Centre Hospitalier Universitaire de Liège, Liege, Belgium
700    1_
$a Comas, Carmina $u Hospital Germans Trias i Pujol, Badalona, Spain
700    1_
$a Kajdy, Anna $u Centre of Postgraduate Medical Education, Obstetrics and Gynecology and Perinatal Medicine, Warsaw, Poland
700    1_
$a Lopez-Tinajero, Maria Fernanda $u Hospital Clinic de Barcelona, Barcelona, Spain
700    1_
$a Figueras, Francesc $u BCNatal, Fetal Medicine Research Center, Hospital Clínic and Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain FFIGUERA@clinic.cat $1 https://orcid.org/0000000344031274
700    1_
$a Gratacos, Eduard $u Hospital Clinic de Barcelona, Barcelona, Spain
710    2_
$a PE37 study group
773    0_
$w MED00184484 $t BMJ open $x 2044-6055 $g Roč. 14, č. 3 (2024), s. e076201
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38458783 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155459 $b ABA008
999    __
$a ok $b bmc $g 2081009 $s 1216529
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c 3 $d e076201 $e 20240308 $i 2044-6055 $m BMJ open $n BMJ Open $x MED00184484
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace